The estimated Net Worth of Gail Schulze is at least $796 mil dollars as of 24 May 2023. Ms. Schulze owns over 9,850 units of Cerus stock worth over $171,011 and over the last 17 years she sold CERS stock worth over $456,717. In addition, she makes $168,434 as Independent Director at Cerus.
Gail has made over 8 trades of the Cerus stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 9,850 units of CERS stock worth $19,996 on 24 May 2023.
The largest trade she's ever made was selling 62,393 units of Cerus stock on 14 December 2020 worth over $456,717. On average, Gail trades about 7,932 units every 67 days since 2007. As of 24 May 2023 she still owns at least 83,420 units of Cerus stock.
You can see the complete history of Ms. Schulze stock trades at the bottom of the page.
Gail Gaumer Schulze serves as Independent Director of the Company. From May 2008 until June 2012, she was the Chief Executive Officer and Chairman of the board of directors of Zosano Pharma, a biopharmaceutical company. From May 2006 to March 2007, she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a then global biopharmaceutical organization. Prior to joining YM Biosciences in 2006, she was President, Chief Executive Officer and director of Eximias Pharmaceutical Corporation, then a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004, Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, then a fully independent biologics subsidiary of Aventis, and from 1997 to 2001, she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997, she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995, Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards. She received a B.A. with highest honors in psychobiology from the University of California, Santa Cruz, studied neurophysiology at the University of Wisconsin and received her M.B.A. from the Stanford Graduate School of Business.
As the Independent Director of Cerus, the total compensation of Gail Schulze at Cerus is $168,434. There are 10 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
Gail Schulze is 68, she's been the Independent Director of Cerus since 2007. There are 3 older and 10 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
Gail's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash y Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: